Pharma News - Chemdiv

GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

LONDON (Reuters) - GlaxoSmithKline has won U.

Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

(Reuters) - Drugmaker Merck & Co Inc (MRK.

Celgene abandons Crohn's drug trials, shares drop

(Reuters) - Celgene Corp said it would abandon testing a drug to treat Crohn’s disease, in a major setback to the U.

Novartis blames site closure on pricing pressure in US generics market

Novartis’ (NOVN.

U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review

PRINCETON, N.

$Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy$

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

FOSTER CITY, Calif.

U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents

DUBLIN, Oct.

Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial

Five months ago, Johnson & Johnson painted sirukumab and talacotuzumab as part of a wave of blockbusters-in-waiting that would drive growth for years to come.

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

INDIANAPOLIS and TÜBINGEN, Germany, Oct.

Drugmakers Amneal, Impax to combine in generics push

(Reuters) - Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing envi...

Pharma and medtech industries prepare for hard Brexit

LONDON (Reuters) - Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small...

Novo Nordisk diabetes drug works; no heart risk-FDA review

(Reuters) - Novo Nordisk A/S’s closely watched diabetes drug semaglutide is effective, caused no heart risk, and carried only limited risk of sight problems, a preliminary review by the U.